HLF gene is a poor prognostic factor in acute myeloid leukemia patients with FLT3-ITD/NPM1 mutations undergoing hematopoietic transplantation
PLOS One · 2025
DOI: 10.1371/journal.pone.0333690 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Xiaoyu Xu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Institute of Hematology, National Center of Hematological Clinical Medicine Research, NHC Key Laboratory of Thrombosis and Hemostasis of Mini…. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Mutation, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Gusu Talent Program.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) patients with FLT3 -ITD mutations were benefit from hematopoietic cell transplantation (HSCT) in the first complete remission. Previous research suggested that newly diagnosed AML patients with high allelic ratio (AR) of FLT3 -ITD have unfavorable survivals, while newly diagnosed AML patients with lower FLT3 -ITD AR and concomitant NPM1 mutations have favorable outcomes. In AML patients with FLT3 -ITD, co-occurrence with DNMT3A , and NPM1 mutations (triple-mutated AML patients) have the worst prognoses, however, it is little known about how these mutations synergize in these triple-mutated AML patients. Here we showed that hepatic leukemia factor ( HLF ) gene was more highly expressed in triple-mutated AML patients than in those without the DNMT3A mutations. We found that HLF gene expressions had significant difference in triple-mutated and FLT3- ITD/ NPM1 AML patients (double-mutated AML patients). Moreover, in DNMT3A mutated AML patients, correlated with high HLF gene expression, which may be itself associated with poor survival rate and drug resistance. Overall our data establish that HLF gene as a novel biomarker in this genetically defined the triple-mutated AML subgroup.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Jiangsu Institute of Hematology, National Center of Hematological Clinical Medicine Research, NHC Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, S…
- Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Suzhou, China.
- Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Soochow University, Suzhou, China.
ORCID-Profile: Hongjie Shen
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Gusu Talent Program
Zitieren
APA
Xu, X., Ge, X., Jiang, A., Chen, J., Qiu, Q., Ding, Z., Zhu, M., Pan, J., Chen, Z., Du, W., Wu, D., Chen, S., & Shen, H. (2025). HLF gene is a poor prognostic factor in acute myeloid leukemia patients with FLT3-ITD/NPM1 mutations undergoing hematopoietic transplantation. PLOS One. https://doi.org/10.1371/journal.pone.0333690
Vancouver
Xu X, Ge X, Jiang A, Chen J, Qiu Q, Ding Z, et al. HLF gene is a poor prognostic factor in acute myeloid leukemia patients with FLT3-ITD/NPM1 mutations undergoing hematopoietic transplantation. PLOS One. 2025. doi:10.1371/journal.pone.0333690
BibTeX
@article{Xu2025,
author = {Xu, Xiaoyu and Ge, Xinxin and Jiang, Airui and Chen, Jia and Qiu, Qiaocheng and Ding, Zixuan and Zhu, Mingqing and Pan, Jinlan and Chen, Zixing and Du, Wenwen and Wu, Depei and Chen, Suning and Shen, Hongjie},
title = {HLF gene is a poor prognostic factor in acute myeloid leukemia patients with FLT3-ITD/NPM1 mutations undergoing hematopoietic transplantation},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0333690}
}
EUVIMED